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Summary
In cerebral malaria, pathological changes can be found in the brain of infected people and in
the brain ofPlasmodium berghei-infected mice. The pathogenesis of cerebral malaria in mice is
believed to be due to an immunopathological reaction giving rise to an excessive production
of cytokines such as interferon y (IFN-'y) and tumor necrosis factor (TNF). We find that low
doses of interleukin 1 (Ilsl) protect mice against cerebral malaria; IIr1 also inhibits parasitemia.
The IIrl effect on parasitemia was not observed in nude mice and was at least partly reversed
in mice treated with 11,1 in combination with antibody to IFN-y, indicating the involvement
of T cells. Mice protected against development of cerebral malaria by IIr1 treatment developed
the syndrome when TNF was given as observed in control infected mice or infected mice treated
with inactivated ID1.
C
erebral malaria is an important cause ofdeath in people
infected with the human malaria parasite Plasmodium
falciparum (1). In aproportionof patients that die from cere-
bral malaria, inflammatory cells, loss of endothelial wall in-
tegrity, and hemorrhages are found in the brain at autopsy
(2, 3). The pathogenesis ofhumancerebral malaria, including
that of the hemorrhages, is largely unexplained.
Similar findings are obtained in a murine malaria model
after infection with P. berghei (4, 5). Infection with this ro-
dent malaria parasite can lead to the development of hemor-
rhages in the brainsofhamsters (6), young rats (unpublished
observations), and mice (4, 5, 7). In P. berghei-infected mice,
the development ofthe hemorrhages coincides with a sudden
and irreversible decrease of the body temperature followed
by rapid death(5). There are indications that a T cell-depen-
dent immunopathological reaction and excessive production
ofcytokines, particularly IFN-y and TNF-a, play an impor-
tant role in the pathogenesis of the brain hemorrhages in in-
fected mice (5, 8). Detrimental and even lethal effects of
cytokines, such as TNF, have also been described in Gram-
negative bacterial infections and endotoxemias (9) . There are,
however, beneficialeffects ofcytokines too. The cytokine 1171,
administered in alow dose to mice, appears to protect mice
from lethal infections due to bacteria such asPseudomonas aeru-
ginosa, Klebsiella pneumoniag Listeria monocytogenes, and fungi
such as Candida albicans (10-14). Although the mechanism
of protection has not yet been elucidated, it is an important
question whether similar protection can be obtained against
a parasitic disease such as lethal cerebral malaria. Therefore,
and because of the strong functional relationship between
TNF and ID1 (15), the effect of low dosages of human rII,
1a and r1L10 was investigated in lethal P. berghei infection
in C57B1/6J mice.
Low-dose IIrl treatment inhibited parasite proliferation in
a dose-dependent way, but only in intact mice, not in T
cell-deficient nude mice. Independent of this effect on para-
site proliferation, IIrl treatment prevented development of
cerebral malaria.
Excessive TNF release is assumed to be responsible for most
of the pathology associated with malaria (16), and exoge-
nous TNF given during infection can acceleratethe develop-
ment of the cerebral syndrome. IIr1 treatment, however, did
not protect against this TNF-accelerated development of ce-
rebral malaria in P. berghei-infected mice.
Materials and Methods
Mice.
￿
C57B1/6J mice were obtained from a local colony and
housed under specific pathogen-free conditions with food (Hope
Farms, Woerden, The Netherlands) and water ad libitum.
Parasite.
￿
P. berghei K173 was maintained by weekly transfer of
parasitized erythrocytes (PE) from infected to naive mice. Ex-
perimental mice were infected with 1,000 PE intraperitoneally.
Parasitemia.
￿
Thin blood films were made from tail blood and
stained with May-Grunwald and Giemsa's solutions.
Body Temperature.
￿
To measure body temperature, the probe of
a digital thermometer (Technoterm; Thermotex, The Hague, The
Netherlands) was inserted in the rectum and read after 18 s.
Light andelectron microscopy ofbraintissue using routine histo-
logical procedures was carried out to detect the presence ofhemor-
rhages.
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￿
HumanMIAs was obtained from Dr. P Lomedico
(Hoffmann-La Roche, Inc., Nutley, NJ). Human rILrls was ob-
tained from Dr. Alan Shaw (Glaxo, Geneva).
Recombinant TNF-a was obtained fromDr. G. R. Adolf, Ernst
Boehringer Institute, Vienna, Austria.
Anti-IFN-y Antibody .
￿
mAb (DB-9) against mouse IFN-y was
obtained from Dr. P.H. van der Meide (TN.O., Rijswijk, The
Netherlands).
Results and Discussion
Various IIA treatments were given to infected mice. When
80 ng of IIrla was given intraperitoneally for six consecu-
tive days, starting on the day of infection, 78% of the mice
were protected against cerebral malaria and experienced only
a limited and transient change in body temperature (Fig. 1
A), whereas all mice that received heat-inactivated IDlot
(100°C for 20 min) developed lethal cerebral malaria (Fig.
1 A and 2). In addition, a remarkable delay of the develop-
ment of the parasitemia was observed in mice treated with
ID1(Fig. 1 B). Although at day 12 parasitemia inIM-treated
micebecame as high as in control mice at day 7 (controlmice
were treated with inactivated IIA), no dramatic decrease in
body temperature and no cerebral hemorrhages occurred in
the IIrl-treated group. Increasing daily dosages up to 320
ng IIr1 showed a further delay in the development of the
parasitemia and again prevented development of cerebral
malaria (Fig. 3). It was found that a single intraperitoneal
injection of80 ng IIrla given3 d after an intravenous infec-
tion with 1,000 parasites prevented death from cerebral
bleedings in 50% (n = 10) of the animals. In addition, in
all mice treated with IIrl on day 3 of infection, the course
of the parasitemia was the same and independent ofdevelop-
ment ofcerebral malaria. This makes it unlikely that protec-
tion against cerebral malaria by IIA treatment is due to its
effect on parasitemia. IIA given as a single injection at day
0 (n = 5) or day 5(n = 5) did not have an effect on parasitemia
and did not prevent cerebral malaria. Perhaps a more impor-
tant observation was that IIA given shortly before the devel-
opment of the cerebral syndrome, i.e., on day 8 (n = 10),
also did not affect the development o£the syndrome. Com-
parable experiments using a 6-d treatment with 11,10 again
showed protection against cerebral malaria and inhibition of
parasitemia. Furthermore, implantation of osmotic pumps
containingIIr1a 2 d before infection (calculated dose, 80 ng
IIA/24 h; pumps active for 20 d) did have a similar effect
on parasitemia and protected against the development ofce-
rebral malaria, as did the 6-d treatment where IIrl was in-
jected daily (n = 5). Inhibition of the proliferation of the
parasite and protection against cerebral malaria were seen as
the main effects from the various IIA treatments.
Based on these observations, a series of experiments was
performed in order to determine a possible mechanism of ac-
tion of 11,1. First, it is known that parasite proliferation is
strongly dependent on erythropoietic activity, probably related
to the parasite's preference for reticulocytes (17), and IIA can
suppress erythropoietinactivity in vitro (18), though its effect
in vivo is less clear(18). Therefore, it was investigated whether
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Figure 1.
￿
Effect of 11A treatment on P . berghei infection in C57B1/6J
mice. Mice were infected with 1,000 parasites intravenously. From day
0 to 5 mice received 80 ng of IIA (0) or inactivated 11A (/) in-
traperitoneally daily. Summarized results from four independent experi-
ments. SD of the mean is indicated as error bars.
or not ILA treatment suppresses erythropoiesis, thereby lim-
iting parasitemia. Erythropoiesis was enhanced by letting 12
drops of blood from the retro-orbital plexus through a he-
matocrit capillary 1 d before IM treatment. 3 d afterbleeding
increased, reticulocyte counts were obtained (untreated con-
trols: 1.2 ± 0.3% ; n = 5), but no difference was found be-
tween mice treated with IIr1 (5.3 ± 2.1% ; n = 6) or inacti-
vated IIA (5.3 ± 3.3%; n = 3). 6 d afterbleeding, reticulocyte
counts had returned to normal values.
Second, since mouse studies have shown that T lympho-
cytes play an essential role in the immunopathology of malaria
(5, 10), we investigated whether IIr1 could influence para-
sitemia in C57B1/6J nude mice (no cerebral malaria in T
cell-deficient mice) Parasitemia was not influenced by IIr1
in these T cell-deficient animals (Fig. 4). Thus, a direct effect
on parasite proliferation is highly unlikely since IL1 is not
effective against parasitemia in nude mice. Apparently, T lym-
phocytes or products of these cells are involved in this pro-
cess, either by specific or nonspecific immunological effects
on the parasite. The fact that the action of IM on the prolifer-
ation ofthe parasite is observed early during infection would
be in favor of a nonspecific effect on the parasite, e.g., via1289
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Figure 3.
￿
Effect of increasing doses of l1rl given from day 0 to 5 on
parasitemia. C57B1/6J mice were infected with 1,000parasitized erythro-
cytes on day 0.
the release of lymphokines such as IFN-y (19) . Indeed, when
infected mice were treated with a combination of
ILI
(80
ng/mouse/dfor 6 d) and anti-IFN-y antibody (1 mg/mouse
1 d before and 6 d after infection), the suppressive effect of ILI
on parasitemia was reversed: 8 d after infection, para-
sitemia in ILl-treated mice was 3.3 ± 3.2% (n = 3), and
in mice treated with ILI and antibody to IFN-y, 7.3 ± 0.9%
(n = 3) (p > 0.06); parasitemia in untreated mice was still
higher (15.7 ± 4.1%; n = 3).
ILI
protection against the
development of cerebral malaria, however, was not reversed
when antibody to IFN-y was added to the treatment. Treat-
ment ofinfected mice with antibody against IFN-y without ILI
had no effect on parasitemia (results not shown). These
data support the hypothesis that IL1-dependent suppression
of parasitemia is at least partly mediated by an ILl-induced
release of IFN-y from T cells.
Specific immunological effects induced by ILI are not ruled
out; ILI can lead to enhanced productionofantibodies (20),
which can contribute to the prevention of the cerebral syn-
drome. Timely treatment with IgG from malaria-immune
mice prevents severe hypothermia as well as the development
of hemorrhages under conditions, where there is no effect
on the course of the parasitemia, indicating that specific an-
tibodies can protect against cerebral malaria (5).
According to our c(ata protection against cerebral malaria
and delayed parasitemia arenot linked. This is in agreement
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